Localization of Phosphatidylserine Binding Sites to Structural Domains of Factor Xa*

Received for publication, June 20, 2001, and in revised form, October 12, 2001
Published, JBC Papers in Press, November 13, 2001, DOI 10.1074/jbc.M105697200

Arvind Srivastava‡, Jianfang Wang‡, Rinku Majumder‡, Alireza R. Rezaie§, Johan Stenflo¶, Charles T. Esmon¶, and Barry R. Lentz‡**

From the ‡Department of Biochemistry & Biophysics, University of North Carolina, Chapel Hill, North Carolina 27599-7260, the ‡Department of Clinical Chemistry, University of Lund, Malmö General Hospital, Malmö S214 01, Sweden, the ‡Department of Biochemistry and Molecular Biology, St. Louis University School of Medicine, St. Louis, Missouri 63104, and the ‡Department of Biochemistry and Biophysics and Pathology, Oklahoma Medical Research Foundation, University of Oklahoma Health Science Center and Howard Hughes Medical Institute, Oklahoma City, Oklahoma 73104

Binding of short chain phosphatidylserine (C6PS) enhances the proteolytic activity of factor Xa by 60-fold (Koppaka, V., Wang, J., Banerjee, M., and Lentz, B. R. (1996) Biochemistry 35, 7482–7491). In the present study, we locate three C6PS binding sites to different domains of factor Xa using a combination of activity, circular dichroism, fluorescence, and equilibrium dialysis measurements on proteolytic and biosynthetic fragments of factor Xa. Our results demonstrate that the structural responses of human and bovine factor Xa to C6PS binding are somewhat different. Despite this difference, data obtained with fragments from both human and bovine factor Xa are consistent with a common hypothesis for the location of C6PS binding sites to different structural domains. First, the γ-carboxyglutamatic acid (Gla) domain binds C6PS only in the absence of Ca$^{2+}$ ($k_d \sim 1 \text{ mm}$), although this PS site does not influence the functional response of factor Xa. Second, a Ca$^{2+}$-dependent binding site is in the epidermal growth factor domains (EGF NC) that are linked by Ca$^{2+}$ and C6PS binding to the Gla domain. This site appears to be the lipid regulatory site of factor Xa. Third, a Ca$^{2+}$-requiring site seems to be in the EGF-C-catalytic domain. This site appears not to be a lipid regulatory site but rather to share residues with the substrate recognition region. Finally, the full functional response to C6PS requires linkage of the Gla, EGF NC, and catalytic domains in the presence of Ca$^{2+}$, meaning that PS regulation of factor Xa involves linkage between widely separated parts of the protein.

The substantial support of soluble phosphatidylserine (C6PS) on the kinetics of prothrombin activation by factor Xa (1) and on the structure of factor Xa, as documented here, indicate that phosphatidylserine (PS) may act as an allosteric regulator of prothrombin activation. PS located on the cytoplasmic face of resting platelet plasma membranes is exposed on the surface of activated platelet vesicles (2, 3). The implication of PS exposure and of the effect of PS on factor Xa and its ability to catalyze activation of prothrombin is that PS may act as a second messenger in regulating thrombin formation. Because of the crucial role of thrombin in hemostasis, the exposure of PS may be a crucial regulatory step in blood coagulation. To better define this regulatory process, it is important to know the locations of the PS binding sites on factor Xa.

The organization of factor X into structural domains is illustrated below in Fig. 1. Factor X consists of two peptides. The light chain consists of an N terminus γ-carboxyglutamatic acid-rich region (Gla module) and two Cys-rich cassette modules. The heavy chain consists of the serine protease catalytic domain. The two cassette modules of the light chain show strong sequence and structural homology to epidermal growth factor (EGF) (4) and are thus referred to as EGFN and EGFc, where N and C indicate the domain nearer to the N and C termini, respectively. Crystal structures of Gla domain-less factor Xa (GDFXa) have been published (5–7). In the most recent of these (7), the EGF cassette modules extend from the catalytic domain to make an extended molecule. In the structure of the analogous serine protease, factor IXa, the EGF module is bent at the inner-EGFc hinge region to right angles with the EGFa, which is tucked along the catalytic module (8). It may be that the EGF modulesform a hinge region that modulates the global structure of factor Xa. The factor IXa structure also differs from that of GDFXa in containing the Gla domain. Although the Gla domain is critical for membrane binding and may modulate the structure of the EGF modules, little is known about the structure of Gla in whole factor Xa. We have only a model structure of factor Xa Gla domain based on the prothrombin Gla domain (9).

Binding of Ca$^{2+}$ to factor X is reportedly required for activation by factor VII/tissue factor or by factor IX/VIII, (10, 11) SpPCa, Spectrozyme PCa; Gla, N-terminus γ-carboxyglutamatic acid-rich region; GDFXa, epidermal growth factor nearest to the N terminus; GDFXc, epidermal growth factor nearest the C terminus; Gla-EGF NC, Gla domain linked to the epidermal growth factor Gla-EGF NC; Gla-EGF NC, Gla domain linked to both epidermal growth factors GDFXa and GDFXc; EGFa, factor Xa construct lacking both the Gla and the EGFa domains; DEGR, [5-(dimethylamino)-1-napthalenesulfonyl]glutamylycylarginyl chloromethyl ketone; GDFXa, factor Xa construct missing the Gla domain; Y99T, GDFXa, mutant in which Tyr-99 is replaced with Thr; CMC, critical micelle concentration.
and for the activity of factor X<sub>a</sub> (12). Ca<sup>2+</sup> binding is also required for PS regulation of factor X<sub>a</sub> proteolytic activity (1). Ca<sup>2+</sup> binds mainly to the Gla module (13), but there also appears to be a high affinity Ca<sup>2+</sup> binding site (k<sub>d</sub> = 160 μM) in the catalytic domain (9, 14–16) and a lower affinity Ca<sup>2+</sup> binding site (k<sub>d</sub> = 0.7–1.2 m M) on the isolated first EGF-like module (4, 12, 16, 17). A Ca<sup>2+</sup>-dependent interaction between the EGF-like and Gla modules appears to enhance the affinity of the site on the EGF-like module to the point that it is tighter (17, 18) (k<sub>d</sub> = 120 μM) than the catalytic domain site. Consistent with this, nuclear magnetic resonance shows that Ca<sup>2+</sup> binding tightens the fold of the isolated EGF<sub>N</sub> domain and bends Gla and EGF<sub>N</sub> domains toward each other around a hinge located in the Gla domain, referred to as a helical or hydrophobic stack (19).

Despite considerable information about Ca<sup>2+</sup> binding to factor X<sub>a</sub>, we have virtually no information about the location of PS binding sites on this key enzyme. The aims of this work have been to locate the lipid regulatory site(s) in factor X<sub>a</sub> and to identify the structural domains of factor X<sub>a</sub> necessary to see the C6PS regulatory effect on factor X<sub>a</sub> activity.

**EXPERIMENTAL PROCEDURES**

**Materials**

1,2-Dicaproyl-sn-glycero-3-phospho-L-serine (C6PS) and 1,2-dicaproyl-sn-glycero-3-phosphocholine (C6PC) were purchased from Avanti Polar Lipids Inc. (Alabaster, AL). Russell’s viper venom factor X-activating protein (RVV-X) was purchased from Hematological Technologies Inc. (Essex Junction, VT), and factor X<sub>s</sub>-specific substrate N-α-benzoylxylocarbonyl-t-arginyl-glycyl-arginine-p-nitroanilide dihydrochloride (S-2765) was purchased from Helena Laboratories (Beaumont, TX). Chymotrypsin was purchased from Worthington (Lakewood, NJ). Chromogenetic substrate Spectrozyme PCa (SpPCa) was purchased from American Diagnostica (Greenwich, CT). [5-(Di-methylamino)-1-napthalenesulfonyl]-glutamylglycylarginyl chloromethyl ketone (DEGR-CK) was purchased from Calbiochem (La Jolla, CA). Diisopropyl fluorophosphate was purchased from Sigma Chemical Co. (St. Louis, MO). All other chemicals were ACS reagent grade or the best available grade.

**Methods**

**Preparation of Factor X<sub>a</sub>—** Bovine factor X was isolated from a barium citrate precipitate obtained from freshly collected bovine plasma (20, 21). Human factor X for stoichiometry and CD measurements was purified from recovered human plasma obtained from the American Red Cross, according to the method of Dahlback et al. (22). Factor X obtained as above was analyzed by SDS-PAGE, concentrated (Centriplus, Amersham Biosciences, Inc., Norwalk, CN). The initial rates of S-2765 hydrolysis were determined using a standard curve obtained in a buffer (50 mM Tris, 175 mM NaCl, pH 7.6) in polypropylene Eppendorf tubes at 37 °C for 5 min before being added to a flat-bottomed polystyrene 96-well plate (Greiner America, Inc.) preincubated at 37 °C. The initial rates of SpPCa amidolysis were determined on a Versamax Tunable Microplate Reader (Moletic Systems, Sunnyvale, CA) at five substrate concentrations (50, 100, 200, 400, and 600 μM) and analyzed in terms of the Michaelis-Menten model using non-linear regression methods available in Sigma Plot 6.0.

**Circular Dichroism Measurements—** Circular dichroism (CD) spectra were measured by recording 250 to 200 nm on an Aviv Model 620S spectrometer (Aviv Associates, Inc., Lake Wood, NJ) in a 1-cm path-length cell at 24 °C with a bandwidth of 1.0 nm. Data points were collected at every 0.5 nm with an average time of 5 s on each point. Each data point was filtered using 0.2-μm filters on an Applied Photophysics P* spectrometer in a 1-mm path-length cell with a bandwidth of 1 nm and data collection at every 0.5 nm. Baseline CD spectra of buffer containing various concentrations of soluble C6PS were collected in the absence and in the presence of 3 mM Ca<sup>2+</sup> and were subtracted from sample spectra. The baseline-corrected digital data were processed, smoothed, and converted to molar ellipticity, Δθ. We have previously determined the critical micelle concentration (CMC) of C6PS at different Ca<sup>2+</sup> concentrations (1), but controls to detect micelle formation were in all cases still performed by watching for sudden drops in ellipticity in the range of 240–250 nm. For human and bovine factor X<sub>a</sub>, the CMC seen in this way was similar to the CMC reported earlier by quasi-elastic light scattering methods (1). The ellipticity ratio θ<sub>222</sub>/ θ<sub>208</sub> was defined as here as a quotient of the mean parameters at a concentration of about 1 mg/ml in 5 mM Tris, 20 mM sodium citrate, 0.6 μM Ca<sup>2+</sup>, pH 7.4. A final purification of factor X was performed 1 day before an experiment by high-performance liquid chromatography on a PerkinElmer Life Sciences Isopure LC system using a Mono Q HR 5/5 ion exchange column (Amersham Biosciences, Inc., Norwalk, CN). The purified factor X was dialyzed into buffer (50 mM Tris, 175 mM NaCl, pH 7.4) for activation. Factor X (10 μM) with 5 mM Ca<sup>2+</sup> was activated at 25 °C with RVV-X that had been covalently linked to agarose beads (10, 23). Factor X<sub>a</sub> was purified by high-performance liquid chromatography on a Mono Q column, and the isolated protein was analyzed by SDS-PAGE electrophoresis. Factor X<sub>a</sub> concentration was measured by determining the rate of S-2765 hydrolysis in a plate reader-based assay (1), using active site-titrated factor X<sub>a</sub> GDFX and the microplate reader-based assay described above. Samples, containing 20 nM protein, various concentrations of C6PS and 3 mM Ca<sup>2+</sup> in a buffer (50 mM Tris, 175 mM NaCl, pH 7.6) containing 0.6% PEG, were incubated at 37 °C for 15 min before measurement. The amidolytic activities were determined from measured initial rates of S-2765 hydrolysis, using a standard curve obtained with active site-titrated factor X<sub>a</sub> (1). Amidolytic activities of GDFX and Y99T were measured using the chromogenetic substrate Spectrozyme PCa (SpPCa) also as described earlier (29). Samples containing 20 nM protein, various concentrations of C6PS (0, 400, 900 μM), and 0.6% PEG (to prevent adsorption of protein to the plate) were incubated in buffer (50 mM Tris, 175 mM NaCl, pH 7.6) in polypropylene Eppendorf tubes at 37 °C for 5 min before being added to a flat-bottomed polystyrene 96-well plate (Greiner America, Inc.) preincubated at 37 °C. The initial rates of SpPCa amidolysis were determined on a Versamax Tunable Microplate Reader (Molecular Devices, Sunnyvale, CA) at five substrate concentrations (50, 100, 200, 400, and 600 μM) and analyzed in terms of the Michaelis-Menten model using non-linear regression methods available in Sigma Plot 6.0.

**Fluorescence Titration of DEGR-E2FX<sub>a</sub> by Soluble C6PS—** Fluorescence intensity measurements were carried out on an SLM 48000 spectrofluorometer (SLM Aminco, Urbana, IL). Slits were closed between measurements to avoid photodegradation of the sample. All buffer solutions were filtered using 0.2-μm filters (Nalgem Co., Rochester, NY). DEGR-EF<sub>x</sub> was prepared by sequential addition of 5 μl of DEGR-CK (1 mg/ml in 0.02 mM Tris, 0.1 mM NaCl, pH 7.5) to 1 ml of about 1 μM purified factor E<sub>FX</sub>. The extent of labeling at the active site was followed by the loss of enzymatic activity, as monitored by the S-2765 assay. Labeling was stopped when no activity remained. DEGR-EF<sub>x</sub> was then dialyzed against 50 mM Tris, 0.1 mM NaCl, pH 7.5, to remove free reagent (37). DEGR-EF<sub>x</sub> (100 μl) in 1 ml of buffer (50 mM Tris, pH 7.5) was incubated in a stirred micro-cuvette (Hellma Cells, Japan, NY) with 0.15 mM NaCl or 3 mM Ca<sup>2+</sup> or both at 25 °C for 20 min. Following additions of C6PS (1–2 μl each addition for a maximum of 3 ml) and of 1 μM DEGR-EF<sub>x</sub>, fluorescence intensity was recorded using an excitation wavelength of 340 nm (bandpass 8 nm) and an emission wavelength of 550 nm (bandpass 4 nm). For each addition, several intensity measurements were performed and averaged and corrected for dilution. Control experiments were per-
formed in which buffer was titrated with soluble lipid in the absence of protein. The lipid solution showed very minor background fluorescence or light scattering signal (which was subtracted from sample signal) until the critical micelle concentration was reached. The critical micelle concentration for C6PS in the presence and absence of 1 mM factor Xα were determined previously to be 0.95 and 2.5 mM, respectively (1). The critical micelle concentrations for C6PC under similar conditions were even higher (1). Data were not analyzed above the critical micelle concentration.

Intrinsic Fluorescence of Gla-EGFNC—Gla-EGFNC (100 nM) in 50 mM Tris, 150 mM NaCl, pH 7.4, in the presence and in absence of 3 mM Ca2⁺ was titrated with soluble C6PS, and the intrinsic fluorescence was monitored at 345 nm (bandpass 4 nm) followed by excitation at 285 nm (bandpass 8 nm). Control experiments were as mentioned for DEG- E_RFX fluorescence.

Phospholipid Sample Preparation—C6PS and C6PC solutions were prepared from measured quantities of 10 mg/ml stock solutions in chloroform. The chloroform was evaporated under a stream of nitrogen. The remaining dry powder was dispersed in the appropriate volume of buffer and vortexed thoroughly to reach a concentration of ~100 mM. The final concentration of this phospholipid stock solution was determined by an inorganic phosphate assay (38).

Data Analysis
In our experiments, we maintained [L] > k_jn, this is roughly a straight line with a slope proportional to n. In our experiments, we maintained [L] > k_jn, but the total lipid concentration had to remain less than the CMC of the lipid. Thus, to obtain n, we had to fit a plot of ΔP versus protein concentration to the non-linear equation given in Equation 1, using standard non-linear regression procedures and the program SigmaPlot (version 6 for Windows 2000; Jandel Scientific).

Data Analysis
In our experiments, soluble lipid was added to the protein solution, and the observed response was taken as representing the fraction of protein bound (f) to lipid at concentration [L] given by,

\[ f = \frac{[L]}{K_D + [L]} \quad \text{(Eq. 2)} \]

where \( K_D \) is the apparent stoichiometric binding constant for soluble lipid binding to the protein. Any observable value that changes from an initial value of \( R_0 \) to a final value at saturation, \( R_{sat} \), as a result of binding can be written as follows,

\[ \frac{R}{R_0} = 1 + \frac{R_{sat} - R_0}{R_0} \times f \quad \text{(Eq. 3)} \]

In the absence and in the presence of 3 mM Ca2⁺ with soluble C6PS concentration is shown in Fig. 2. The highest C6PS concentration used (0.8 mM) was still below the CMC for C6PS in the presence of 3 mM Ca2⁺ (~2.5 mM) (1). The amidolytic activities of factor Xα and GDFXα were decreased by 79% and 16%, respectively, at saturation with C6PS (Table I), but C6PS had negligible effect on the amidolytic activity of E2FXα. The functional responses of factor Xα and its constructs to C6PS binding were reasonably well described by a single binding site model (see “Methods”), and the binding parameters are given in Table I. The apparent \( K_d \) for C6PS binding to the expressed human factor Xα in this experiment (39 ± 6 μM) was comparable to but somewhat smaller than we have reported previously for factor Xα isolated from outdated human plasma (65 ± 5 μM) (1), and the percent inhibition was also greater (80 versus 60%). This probably reflects the slight difference between Xα from human plasma and factor Xα from a single CDNA clone, as used here.

Effect of Soluble C6PS on the CD Spectra of Expressed Human Factor Xα and Its Constructs—The effects of soluble C6PS on the CD spectra of expressed human factor Xα and its constructs, GDFXα and E2FXα, were studied in the absence and presence of 3 mM Ca2⁺. CD spectra of human factor Xα were shown at various concentrations of C6PS in the presence (Fig. 3A) and in the absence of 3 mM Ca2⁺ (Fig. 3B). Although it is reported to bind Ca2⁺ (17), human factor Xα did not undergo a detectable change in secondary structure upon addition of 3 mM Ca2⁺, as seen from the solid and dotted curves in Fig. 3A and from the \( \theta_{222}/\theta_{208} \) ratio and α-helical content (Table I). Secondary structure analysis yielded an estimate of 11% helical content in the presence or absence of Ca2⁺, in good agreement with the reported helicity for the analogous factor IXα crystal structure (10.6%) (8). However, there was a substantial change in CD upon addition of C6PS to human factor Xα in the presence of 3 mM Ca2⁺ (Fig. 3A). By contrast, there was only a small change in CD upon addition of C6PS in the absence of Ca2⁺. The variation of ellipticity ratio (\( \theta_{222}/\theta_{208} \)) for human factor Xα with C6PS concentration is shown as an inset in Fig. 3 (A and B) in the presence and absence of Ca2⁺, respectively.

The variations of ellipticity ratio of GDFXα and E2FXα with C6PS concentration are shown in Fig. 4 (B and C, respectively).

The smooth lines through the data result from fitting the data to a single-binding-site model as described under “Methods.” The stoichiometric binding constants (\( K_n \)) and percent changes in \( \theta_{222}/\theta_{208} \) at saturation (\( \Delta \theta_{222}/\theta_{208} \times 100 \%), resulting in the least square fits, are reported in Table II. We stress that \( K_n \) values obtained in this way cannot be interpreted as site binding constants (\( k_j \)), because the number of data points taken and their intrinsic accuracy were not sufficient to define a binding mechanism in terms of the number, affinities, and responses of different sites present on each peptide fragment. However, the data in Fig. 4 do establish, in most cases, which fragments do bind C6PS, the magnitude of the total response (shifts in secondary structure), and the fraction of sites occupied at any lipid concentration (from \( K_n \) values). The ellipticity ratio of factor Xα decreased by 6% upon saturation with C6PS in the absence of Ca2⁺ and by 16% when saturated with C6PS in the presence of 3 mM Ca2⁺. Similarly, the α-helical content decreased by 1 and
containing 50 mM Tris, 175 mM NaCl, 0.6% PEG, at pH 7.6. Absolute factors each bind two molecules of C6PS, and their amidolytic activities were sensitive to the presence of C6PS. Although E2FXa binding to C6PS amidolytic activities of human factor Xa, GDFXa, and E2FXa in the presence of 3 mM Ca2+ were 1.40, 0.83, and 0.79 M S-2765/s/

Rates of S-2765 amidolysis by factor Xa (EGFn and EGFC) and the catalytic domain are also shown. The construct missing the Gla domain is referred to as GDFXa, and the domain missing the Gla and EGF domain is called E2FXa. Results in the absence of Ca2+ are summarized below the factor Xa diagram: bovine Gla, Gla-EGF N, and Gla-EGF NC CD spectra all responded to C6PS. Stoichiometry measurements showed that Gla domain binds to one molecule of C6PS, whereas the Gla-EGF NC domain binds to two molecules. Neither stoichiometry nor CD measurements showed an interaction of C6PS with E2FXa binding to C6PS, an interaction confirmed by CD. Results in the presence of Ca2+ are summarized above the factor Xa diagram: bovine Gla and Gla-EGF N did not bind to C6PS, but Gla-EGF NC domain binds to one molecule of C6PS and also showed a change in CD spectrum and intrinsic fluorescence with C6PS. Human E2FXa, GDFXa, and factor Xa all showed altered CD spectra with C6PS. GDFXa and factor Xa each bind two molecules of C6PS, and their amidolytic activities were sensitive to the presence of C6PS. Although E2FXa binding to C6PS was detected with CD and fluorescence, its amidolytic activity was unchanged with the addition of C6PS.

The effect of soluble C6PS on amidolytic activities of human factor Xa and its constructs, GDFXa and E2FXa. The initial rates of S-2765 amidolysis by factor Xa, human factor Xa, human GDFXa, and human E2FXa (triangles) are plotted as a function of C6PS concentrations in the presence of 3 mM Ca2+. Rates were measured at 37 °C in a buffer containing 50 mM Tris, 175 mM NaCl, 0.6% PEG, at pH 7.6. Absolute amidolytic activities of human factor Xa, human factor Xa, human GDFXa, and human E2FXa, in the absence of C6PS were 1.40, 0.83, and 0.79 M S-2765/s/µM enzyme, respectively. The absolute activities were calculated based on an extinction coefficient for S-2765 at 205 nm.

3%, respectively (Table II). There was an 18% decrease in the Kd of GDFXa but only a slight (0.8%) decrease in helical content in response to soluble C6PS in the presence of 3 mM Ca2+. This discrepancy between changes in θ222/θ208 and helical content suggests that GDFXa binding to C6PS involves more than a change in helical content. Neither the θ222/θ208 ratio nor the helix content changed upon addition of C6PS in the absence of C6PS (Fig. 4B, Table I). Human GDFXa seems to bind soluble C6PS in the presence of 3 mM Ca2+ with its structural response being comparable to that of whole human factor Xa, but seems not to bind C6PS in the absence of Ca2+, at least not with a measurable structural response. The θ222/θ208 ratio of E2FXa decreased by 18% upon addition of saturating concentrations of C6PS in the presence of 3 mM Ca2+ but remained unchanged in the absence of Ca2+. The 10% decrease in ellipticity ratio was significantly smaller than that seen either for native human factor Xa (16%) or for GDFXa (16%).

The effect of soluble C6PS on the CD Spectra of Bovine Factor Xa and Its Domains—The CD spectra of bovine factor Xa, its Gla, Gla-EGF N, Gla-EGF NC, and Gla-EGF NC domains were also collected and analyzed in terms of θ222/θ208 and α-helical content. The variations of ellipticity ratio (θ222/θ208) with C6PS concentration in the presence (closed circles) and absence (open circles) of 3 mM Ca2+ for factor Xa, Gla, Gla-EGF N, and Gla-EGF NC domains, are shown in Fig. 4 (A, D, E, and F, respectively). The smooth curves through these data result from fitting the data to a single-site binding model (see “Methods”), with binding constants (Kb) and fractional changes in θ222/θ208 at saturation (ΔR222) reported in Table II. The θ222/θ208 ratio of bovine factor Xa decreased by 16% upon addition of saturating concentration of C6PS in the absence of Ca2+ but increased by 26% in the presence of 3 mM Ca2+ (Table II). These same spectra were analyzed to reveal changes in α-helical content of −1 and +6%, respectively (Table II).

Comparison of changes in α-helical content with changes in θ222/θ208 ratios for human and bovine factor Xa, and their
fragments (Table II) makes it clear that there is a general correlation between these two parameters, but that the \( \frac{\theta_{222}}{\theta_{208}} \) ratio reflects more than just helical content. It is also clear from comparison of the responses of bovine and human factor Xa to C6PS that the secondary structural changes associated with C6PS binding are different for these two proteins (Table II). However, CD spectra for bovine Xa taken under the same conditions used for the spectra in Fig. 3 were qualitatively similar to the human Xa spectra shown in Fig. 3. To make a more quantitative comparison of these two proteins, we collected spectra down to 185 nm in a buffer identical to that used for Fig. 3, except it lacked NaCl and was therefore much more transparent in the deep UV spectrum (34). Dialysis of bovine factor Xa into this buffer and then return to a normal 150 mM NaCl buffer over a period of 48 h had no measurable effect on the ability to bind C6PS or on the amidolytic activity of factor Xa toward S-2765 substrate. Secondary structure analysis of the bovine and human protein spectra in a NaCl-free buffer revealed no difference between the two of greater than 0.9% of helical, beta, turn, or unstructured content. As expected, because Na\(^+\) is needed for Ca\(^{2+}\) binding (35, 36) and Ca\(^{2+}\) is needed for C6PS binding (1), there was no significant change in secondary structure content upon addition of either Ca\(^{2+}\) or C6PS to either protein in the buffer lacking NaCl. Thus, spectra of this quality could not be used to quantify the different effects of C6PS on bovine and human factor Xa secondary structure, but were useful to establish the expected structural similarity between these two analogous proteins.

The ellipticity ratio of the Gla domain increased by 43%, while \( \alpha \)-helicity increased by 1.8% upon addition of 3 mM Ca\(^{2+}\) (Fig. 4D at 0 mM C6PS). In the absence of Ca\(^{2+}\), the ellipticity ratio increased by 97% at saturation with C6PS while \( \alpha \)-helicity increased by 2.1% (Table II). However, no measurable change was seen in the presence of 3 mM Ca\(^{2+}\). This suggests the presence of at least one Ca\(^{2+}\)-masked soluble lipid binding site in the Gla domain of bovine factor Xa, but no Ca\(^{2+}\)-dependent site. This site was not specific for PS, because C6PC also bound to the Gla domain in the absence of Ca\(^{2+}\) (data not shown).

Ca\(^{2+}\) bound to the EGF\(_N\) domain of factor Xa and induced a large decrease in the ellipticity ratio (81%) but no change in the \( \alpha \)-helical content (Table II). This is not surprising, because the solution structure of bovine factor Xa EGF\(_N\) is reported to consist almost entirely of anti-parallel \( \beta \)-sheets and turns (39) and Ca\(^{2+}\) binding to Gla-EGF\(_N\) seems not to alter its fold (19).

This is another example of how the disparity between estimates by two different algorithms (33). The disparity between estimates by the two methods was always <10% of the estimates.

The CMC of C6PS was examined as above in the presence of 0 mM (dashed line), or 0.6 mM C6PS (solid line), or 0.2 mM C6PS (dotted line), and in the absence of Ca\(^{2+}\). The CMC of C6PS to either protein in the buffer lacking NaCl. Thus, spectra of this quality could not be used to quantify the different effects of C6PS on bovine and human factor Xa secondary structure, but were useful to establish the expected structural similarity between these two analogous proteins.

The ellipticity ratio of the Gla domain increased by 43%, while \( \alpha \)-helicity increased by 1.8% upon addition of 3 mM Ca\(^{2+}\) (Fig. 4D at 0 mM C6PS). In the absence of Ca\(^{2+}\), the ellipticity ratio increased by 97% at saturation with C6PS while \( \alpha \)-helicity increased by 2.1% (Table II). However, no measurable change was seen in the presence of 3 mM Ca\(^{2+}\). This suggests the presence of at least one Ca\(^{2+}\)-masked soluble lipid binding site in the Gla domain of bovine factor Xa, but no Ca\(^{2+}\)-dependent site. This site was not specific for PS, because C6PC also bound to the Gla domain in the absence of Ca\(^{2+}\) (data not shown).

Ca\(^{2+}\) bound to the EGF\(_N\) domain of factor Xa and induced a large decrease in the ellipticity ratio (81%) but no change in the \( \alpha \)-helical content (Table II). This is not surprising, because the solution structure of bovine factor Xa EGF\(_N\) is reported to consist almost entirely of anti-parallel \( \beta \)-sheets and turns (39) and Ca\(^{2+}\) binding to Gla-EGF\(_N\) seems not to alter its fold (19). This is another example of how the disparity between estimates by two different algorithms (33). The disparity between estimates by the two methods was always <10% of the estimates.
either in the presence or in the absence of Ca$^{2+}$ (Table II). The Gla-EGFN domain pair also bound to Ca$^{2+}$ and induced a 140% increase in ellipticity ratio (Fig. 4E). In terms of secondary structure, this translated into a large increase in $\theta_{222}/\theta_{208}$ and a nearly insignificant decrease in $\alpha$-helical content (Tables I and II). It is known from NMR studies that Gla-EGFN undergoes a significant structural reorganization in which the EGF and Gla domains fold onto each other upon binding Ca$^{2+}$ (19).

C6PS induced a structural change in Gla-EGFN in the absence of Ca$^{2+}$ ($\theta_{222}/\theta_{208}$ increased by 333% and helicity increased by 2.3%, Fig. 4E and Table II), but no C6PS-dependent change was detected in the presence of 3 mM Ca$^{2+}$. The change in $\theta_{222}/\theta_{208}$ seen in the absence of Ca$^{2+}$ was much greater than seen for the Gla domain (Table II). Because EGFN showed no change in response to C6PS, this implies that C6PS binding to Gla-EGFN in the absence of Ca$^{2+}$, like the binding of Ca$^{2+}$ in the absence of C6PS (19), involves linkage between the Gla and EGFN domains.

Unlike Gla-EGFN, Gla-EGFNC interacted with soluble C6PS in the presence of Ca$^{2+}$ ($\theta_{222}/\theta_{208}$ increased by a barely perceptible 10% while helicity also increased by only 1.1%) as well as in its absence ($\theta_{222}/\theta_{208}$ and helicity increased by 121 and 2.8%, respectively).

**Stoichiometry of C6PS Binding to Factor Xα and Its Fragments**—To test and extend our CD observations, C6PS binding to bovine and human factor Xα, and their fragments was also monitored by equilibrium dialysis, a direct binding measurement. Because of the large quantities of protein needed for these measurements, it was not possible to obtain complete binding isotherms by this method. However, using dissociation constants estimated from our CD data, it was possible to estimate binding stoichiometries (see Equation 1 under “Methods”). The measured stoichiometries of C6PS binding to various fragments in the presence and in the absence of 3 mM Ca$^{2+}$ are shown in Table III. Human factor Xα binds two molecules of C6PS in the presence and one in the absence of 3 mM Ca$^{2+}$, respectively, just like bovine factor Xα (GDFXα) also bound two molecules of C6PS in the presence of Ca$^{2+}$ but did not bind to C6PS in the absence of Ca$^{2+}$. The bovine Gla domain bound one molecule of C6PS in the absence of Ca$^{2+}$ and did not bind C6PS in the presence of 3 mM Ca$^{2+}$, consistent with the lack of any change in $\theta_{222}/\theta_{208}$ under these conditions (Fig. 4D). When the Gla domain was linked to the EGFNC domain, it bound two molecules of C6PS in the absence and one molecule of C6PS in the presence of 3 mM Ca$^{2+}$. Stoichiometry measurements were thus all consistent with the results of our CD experiments. Together, these results provide a clear and self-consistent picture of the distribution of C6PS binding sites on factor Xα (Fig. 1).

**Fluorescence of Gla-EGFNC Titrated with C6PS**—Because the C6PS-induced change in secondary structure in the Gla-EGFNC domain triplet was so small (Fig. 4F), we tested further for a C6PS-induced conformational change by titrating the intrinsic fluorescence of Gla-EGFNC with soluble C6PS in the absence (open circles) and presence (closed circles) of 3 mM Ca$^{2+}$, with the results shown in Fig. 5. The curves passing through the data were obtained by fitting the data to the single binding site model (see “Methods”), yielding dissociation constants for C6PS binding to Gla-EGFNC in the presence and absence of Ca$^{2+}$ were 203 ± 63 and 470 ± 74 μM, respectively. These binding constant are comparable to those obtained by CD measurements (Table II). We conclude that Ca$^{2+}$-dependent binding of C6PS produced conformational changes in the Gla-EGFNC domain triplet.

**Fluorescence of DEGR-E2FXα Titrated with C6PS**—Although CD data suggest that a Ca$^{2+}$-requiring site might be located in the E2FXα fragment, we could not confirm this by direct stoichiometry measurement due to a lack of sufficient quantities of this expressed protein. To confirm the Ca$^{2+}$-requiring binding site in to the E2FXα fragment, we labeled E2FXα with DEGR-CK and monitored the change of fluorescence intensity of DEGR-E2FXα, as a function of C6PS. The binding analysis was performed with two preparations of DEGR-E2FXα, and the results are presented in Fig. 6, with the results from the two preparations distinguished by closed circles and closed squares. The results clearly show a saturable drop in DEGR-E2FXα fluorescence in the presence of Na$^+$ and Ca$^{2+}$, although no change was detected when either Ca$^{2+}$ (open triangles) or Na$^+$ (open circles) were missing. This requirement for Na$^+$ and Ca$^{2+}$ for C6PS binding to E2FXα raises the possibility that the site in the E2FXα fragment might be the amine binding site that is also reported to require Ca$^{2+}$ and Na$^+$ (40). A global fit of a single-site binding model to the two data sets obtained in the presence of both Na$^+$ and Ca$^{2+}$ is shown by the solid hyperbolic curve.

**Effect of Soluble C6PS on the Amidolytic Activities of Expressed Human GDFXα and Its Mutant Y99T**—To better establish the identity of the C6PS site located in the E2FXα fragment, we monitored hydrolysis of SpPCa by GDFXα and its mutant Y99T as a function of soluble C6PS, in buffer containing 50 mM Tris, 150 mM NaCl at pH 7.4 in the presence of 3 mM Ca$^{2+}$ (open circles) and in the absence of Ca$^{2+}$ (open circles). Fluorescence intensities of Gla-EGFNC were measured following an equilibrium period of 4 min after each addition of C6PS. The curves passing through the data were obtained by fitting the data to a single binding site model (see “Methods”), yielding dissociation constants for C6PS binding to Gla-EGFNC in the presence and in the absence of Ca$^{2+}$ of 203 and 470 μM, respectively.

![Graph](Image 340x597 to 522x729)

**Table III**

Stoichiometry determination for soluble C6PS binding to various fragments of human and bovine factor Xα in the presence and absence of 3 mM Ca$^{2+}$

| Species       | Stoichiometry | C6PS concentration used | μM |
|---------------|---------------|--------------------------|----|
| Human Xα      | 1.75 ± 0.03   | 400                      |
| Human GDFXα   | 1.96 ± 0.09   | 600                      |
| Bovine Gla-EGFNC | 0.97 ± 0.07 | 400                      |
| Bovine Gla    | NC*           | 400                      |

*No change in lipid concentration detected between two chambers, i.e., no binding detected.

| No Ca$^{2+}$ | Human Xα | 0.93 ± 0.07 | 400 |
|--------------|----------|-------------|----|
| Human GDFXα  | NC*      | 600         |
| Bovine Gla-EGFNC | 1.76 ± 0.05 | 800 |
| Bovine Gla   | 0.96 ± 0.12 | 400         |
Fig. 6. Response of DEGR-E2FXa fluorescence to titration by soluble C6PS. 100 nM human DEGR-E2FXa was titrated with soluble C6PS in buffers: 50 mM Tris, 3 mM CaCl2 (closed circles and closed squares representing two independent preparations of DEGR-E2FXa); 50 mM Tris, 3 mM CaCl2 (open circles); and 50 mM Tris, 150 mM NaCl (open triangles) at pH 7.4. Fluorescence intensities were measured 4 min after each addition of C6PS. A global fit of a single-site dissociation constant of 27 \( \mu \text{M} \) in the absence of Ca2+ is shown in the inset.

Fig. 7. The effect of soluble C6PS on the amydolitic activities of expressed human GDFXa and its mutant Y99T. The initial rates of SpPCa amidolysis by GDFXa (closed triangles) and Y99T (open triangles) in the absence of Ca2+ are plotted as a function of C6PS concentration. Rates were measured at 37 °C in a buffer containing 50 mM Tris, 175 mM NaCl, 0.6% PEG, at pH 7.6. The hyperbolic line passing through the Y99T data was obtained by fitting the data to the single-binding-site model, which yielded a dissociation constant of \( 4.10^{9} \text{M} \). The initial rates of Y99T amidolysis were determined at 0, 400, and 900 \( \mu \text{M} \) C6PS concentrations and at 50, 100, 200, 400, and 600 \( \mu \text{M} \) substrate concentrations. From these data, we determined the \( k_{\text{cat}} \) and \( K_{\text{cat}} \) values for SpPCa amidolysis by Y99T at three lipid concentrations. The variation of \( k_{\text{cat}}/K_{\text{cat}} \) (circles) and \( K_{\text{cat}} \) (squares) with the C6PS concentration is shown in the inset.

exists in the catalytic domain and shares at least some residues with the substrate binding site. Like binding of C6PS, this site was both Ca2+ - and Na+ -dependent. The variation of amidolitic activities as a function of C6PS concentrations is shown in Fig. 7. As expected, because no C6PS binding site was detected in GDFXa in the absence of Ca2+, soluble C6PS did not have any effect on the rate of hydrolysis of SpPCa by GDFXa (closed triangles). However, the rate of hydrolysis of SpPCa by the Y99T GDFXa mutant decreased with the addition of C6PS, and the binding curve (open triangles) was fitted to a single-binding-site model with an apparent stoichiometric dissociation constant of 410 \( \mu \text{M} \). It appears that the Ca2+-requiring C6PS binding site in GDFXa becomes independent of Ca2+ as a result of the Y99T mutation. This result clearly proves that residue Tyr-99, which is known to be part of a reported amine binding site and the substrate binding site (40), plays a role in C6PS binding to the Ca2+-requiring site located in the E2FXa fragment. The question still remains: Are the C6PS site and the substrate binding site one and the same? To answer this question, we monitored the effect of C6PS on the \( k_{\text{cat}} \) and \( K_{\text{cat}} \) for SpPCa hydrolysis by Y99T GDFXa in the absence of Ca2+. As shown in the inset in Fig. 7, \( k_{\text{cat}} \) remained constant with C6PS concentration but \( K_{\text{cat}} \) increased in a hyperbolic fashion with an increase in lipid concentration. This means that C6PS competes with substrate for the substrate binding site, just as tertiary amines have been shown to do (40). We conclude that the Ca2+-requiring C6PS binding site shares some ligand-recognition residues with the substrate binding site. We report elsewhere that the Ca2+-requiring site minimally recognizes glyceroephosphorylserine and does not bind phosphatidylcholine.3 Because the amine binding site recognizes choline (40), it is unlikely that the C6PS site and the amine site are identical, but they likely share some ligand recognition regions with each other and with the substrate binding site.

**DISCUSSION**

We have shown previously (1) that soluble C6PS enhanced factor Xa’s proteolytic activity by about 60- to 70-fold. The purpose of this work was to locate the C6PS effector sites to one or more domains of factor Xa. Our results have located three sites on this serine protease but suggest that only one is involved in functional regulation. These results support a reasonable hypothesis for how one molecule of regulatory C6PS and two molecules of non-regulatory C6PS are bound to factor Xa. This hypothesis is summarized in Fig. 1. The arguments in favor of this hypothesis are summarized below.

**One Ca2+-masked Phospholipid Site Is Located in the Gla Domain—**As expected (42), the secondary structure of the Gla domain was sensitive to the presence of 3 mM Ca2+ (compare open and closed circles of Fig. 4D at 0 mM C6PS) with the change elicited by Ca2+ being a 43% increase in \( \Theta_{222}/\Theta_{208} \) and a 1.8% increase in \( \alpha \)-helical content. However, the C6PS site in the Gla domain was masked by Ca2+, because no structural response was seen (Fig. 4D). This is surprising, because binding of Gla-containing proteins to PS-containing membranes has long been seen as mediated by a Ca2+-induced conformational change of the Gla domain (43–46). It may be that binding of Gla-containing proteins to PS-containing membrane involves adsorption of the Ca2+-conformation of the Gla domain to a membrane surface (31, 47–48) rather than recognition of individual PS molecules by specific binding sites. By contrast, the C6PS-induced conformational change that we see in the absence of Ca2+ does involve a single C6PS molecule (Table III). Because neither human (1) nor bovine factor Xa respond functionally to C6PS in the absence of Ca2+, it is unlikely that this Ca2+-masked site could by itself be a regulatory site.

**Two C6PS Sites Exist in the Factor Xa Fragment that Lacks the Gla Domain (GDFXa)—**Our stoichiometry measurements showed that GDFXa binds two molecules of C6PS in the presence of 3 mM Ca2+ (Table III). Both of these sites are Ca2+-dependent, because there was no detectable change in \( \Theta_{222}/\Theta_{208} \) (Fig. 4B, open circles), and the stoichiometry was nearly zero (Table III) in the absence of Ca2+, meaning binding of C6PS in the absence of Ca2+ is at best quite weak.

**The EGF and Gla Domains Are Structurally Linked by C6PS Binding—**The EGF Xa domain alone did not respond structurally to C6PS, in either the presence or absence of Ca2+ (Table II). In the absence of Ca2+, however, when linked covalently to the Gla domain, the EGF Xa domain either experienced a large conformational change (\( \Delta \Theta_{222}/\Theta_{208} = 333% \)) or modified in a major way the response of the Gla domain (\( \Delta \Theta_{222}/\Theta_{208} = 97% \)) to C6PS. Based on a comparison of the structural changes for Gla and Gla-EGF Xa on the low helical content of these two domains in homologous factor IXa (8), it would appear most likely that the response being monitored in Gla-EGF Xa is not

---

3 M. Banerjee, D. C. Drummond, A. Srivastava, D. Daleke, and B. R. Lentz, submitted for publication.
that of the Gla domain and is not a change in $\alpha$-helix content, but is a change in the EGF$_N$ module that requires conformational linkage to the Gla domain. Like Gla, Gla-EGF$_N$ did not bind C6PS in the presence of Ca$^{2+}$, so the Gla-EGF$_N$ site seen in the absence of Ca$^{2+}$ must involve the Ca$^{2+}$-masked site in the Gla domain. Ca$^{2+}$-mediated conformational linkage between the Gla and EGF$_N$ domains of factor X$_\alpha$ is well established (14, 19), and our results imply that this linkage involves a C6PS binding site as well.

Unlike the Gla-EGF$_N$ fragment, the Gla-EGF$_{NC}$ fragment experienced a structural change induced by C6PS both in the presence and absence of Ca$^{2+}$, although the changes seen in the presence of Ca$^{2+}$ were qualitatively different from those seen in its absence (Figs. 4F and 5). Stoichiometry measurements showed that Gla-EGF$_{NC}$ binds one C6PS molecule in the presence of Ca$^{2+}$ and two in the absence of Ca$^{2+}$ (Table III). Based on these observations, Gla-EGF$_{NC}$ seems to have two types of C6PS sites. One is the Ca$^{2+}$-masked site in the Gla domain, and one is a site that does not require Ca$^{2+}$ to recognize C6PS but that binds C6PS much more tightly in the presence of Ca$^{2+}$ than in its absence (Table II and Fig. 5). The Ca$^{2+}$-dependent site requires linkage of all three N-terminal modules (Gla, EGF$_N$, and EGF$_C$) for a full response. Ca$^{2+}$ is known to link the EGF$_N$ and Gla domains (14, 19), and Ca$^{2+}$ masks the C6PS site in the Gla domain. For these reasons, we suggest that Ca$^{2+}$ links the C6PS sites in the Gla-EGF$_N$ and EGF$_{NC}$ domains to create one site having higher affinity for C6PS than either of the individual sites. If so, we expect that the sandwich formed by the Ca$^{2+}$-linked Gla and EGF$_N$ domains (19) will form an important element of this binding site.

A Ca$^{2+}$-requiring Site in the EGF$_C$-catalytic Domain Is Probably Part of the Substrate Recognition Site—Direct measurement of stoichiometry by equilibrium dialysis measurements showed two C6PS binding sites in GDFX$_\alpha$ in the presence of Ca$^{2+}$ and none in the absence of Ca$^{2+}$ (Table III). We know that one of these Ca$^{2+}$-dependent sites must be in the EGF$_{NC}$ pair. A Ca$^{2+}$-requiring site is in the E$_2$FX$_\alpha$ fragment (Figs. 4C and 6). Our experiment with the Y99T mutant of GDFX$_\alpha$ showed that C6PS binding to the Ca$^{2+}$-requiring site in the E$_2$FX$_\alpha$ fragment competes with binding of substrate (inset to Fig. 7). In addition, C6PS binding to GDFX$_\alpha$ was altered by the Y99T mutation and Y99 is known to be part of the substrate recognition site (40). From these observations, we conclude that the Ca$^{2+}$-requiring C6PS site in E$_2$FX$_\alpha$ at least overlaps the substrate recognition site. This is consistent with the fact that substrate recognition is also linked to Na$^{+}$ and Ca$^{2+}$ binding (35, 36). Because this site is located roughly 60 Å from the membrane surface (37), it is unlikely to be involved in regulating activity in vivo.

The Functional Response to C6PS Seems to Require Minimally the EGF$_{NC}$ Pair and the Catalytic Domain—it is known that the proteolytic activity of factor X$_\alpha$ is enhanced roughly 60- to 70-fold by binding of C6PS (1). The change in amidolytic activity of the GDFX$_\alpha$ fragment upon titration with C6PS clearly followed a single-site-binding model (Fig. 2), suggesting either that only one site regulates activity or that the two sites are equivalent in their abilities to modulate activity. This fragment consists of a pair of EGF-like domains and a catalytic domain. Our data show that one C6PS site is located at or near the substrate recognition site (Fig. 7) and that one site is most likely in the EGF$_{NC}$ pair (Fig. 1 and Tables I–III). It appears for three reasons that regulation of activity by C6PS requires the site in the EGF$_{NC}$ pair. First, the substantial amidolytic activity toward S-2765 of the E$_2$FX$_\alpha$ fragment did not respond to C6PS (Fig. 2), although E$_2$FX$_\alpha$ did undergo a C6PS-induced conformational change that required Ca$^{2+}$ (Fig. 6). Second, the $K_d$ for the Ca$^{2+}$-dependent structural response of bovine Gla-EGF$_{NC}$ to C6PS (155 μM, Table II) was similar to that for the activity response of bovine factor X$_\alpha$ (167 μM). Finally, the site in the EGF$_{NC}$ pair can be occupied in the presence or absence of Ca$^{2+}$ (see Figs. 4F and 5 and Table II), but with very different $K_d$ values and structural responses under these two circumstances (Table II). In the absence of Ca$^{2+}$, the response to C6PS seems to depend only on the linkage of Gla to EGF$_N$, while in the presence of Ca$^{2+}$, the complete EGF$_{NC}$ pair is needed. Because factor X$_\alpha$ is active only in the presence of Ca$^{2+}$, we conclude that the site that regulates activity requires both the EGF domains. The fact that the response of GDFX$_\alpha$ activity to C6PS was only about a tenth that of whole factor X$_\alpha$ implies that the regulatory site is in the EGF$_{NC}$ domain but that linkage to the Gla domain is essential for optimal changes in the catalytic domain’s active site.

**Bovine and Human Factor X$_\alpha$ Have Analogous C6PS Binding Sites**—Based on our results, we have noted that the bovine and human forms of factor X$_\alpha$ show different structural responses to C6PS despite having very similar secondary structures in solution. If their responses to C6PS are different, it could also be that the location of C6PS binding sites might be different and our use of data from both bovine N-terminal fragments (Gla, Gla-EGF$_N$, and Gla-EGF$_{NC}$) and human C-terminal biosynthetic fragments from cDNA constructs (X$_\nu$, GDFX$_\alpha$, E$_2$FX$_\alpha$) would be flawed. Based on the analysis provided below that is based on careful inspection of the diagram in Fig. 1 summarizing all our observations, we argue that this is not the case.

Data obtained with the human $X$ fragments clearly show that a single Ca$^{2+}$-requiring C6PS site exists in E$_2$FX$_\alpha$. The existence of this site in the catalytic domain was confirmed by our titration of DEGR-E$_2$FX$_\alpha$ fluorescence in the absence of Na$^{+}$ and by titration of the activity of the Y99 mutant of GDFX$_\alpha$ in the absence of Ca$^{2+}$. Titrations of the amidolytic activity of these biosynthetic human factor X$_\alpha$ fragments show that another site exists in the EGF$_{NC}$ pair and this site regulates factor X$_\alpha$ activity. This second site was either absent or too weak to be detected in the absence of Ca$^{2+}$. Because a single C6PS bound to whole factor X$_\alpha$ and none bound to GDFX$_\alpha$ in the absence of Ca$^{2+}$, there must be a Ca$^{2+}$-masked C6PS binding site in the Gla domain. The very different responses of whole factor X$_\alpha$ and GDFX$_\alpha$ in the presence of Ca$^{2+}$ (Fig. 2) to C6PS shows that linkage of the Gla and EGF$_{NC}$ modules is needed for a full functional response.

If we consider the experiments done with N-terminal fragments of bovine factor X$_\alpha$, we see clearly that a Ca$^{2+}$-masked C6PS site exists in the Gla domain. We see as well that a single Ca$^{2+}$-dependent (but not requiring) site exists in Gla-EGF$_N$. This site requires the linkage of the Gla, EGF$_N$, and EGF$_C$ modules. Because two C6PS bind to whole bovine factor X$_\alpha$ in the presence of Ca$^{2+}$, there must be a second site in the catalytic domain.

We argue from this analysis that data obtained with bovine and human fragments lead independently to nearly the same conclusions. This means both that the bovine and human proteins interact similarly with C6PS (as expected for such highly homologous proteins) and that the two sets of data with proteins from different species support and confirm each other.

**REFERENCES**

1. Koppaka, V., Wang, J., Banerjee, M., and Lentz, B. R. (1996) *Biochemistry* **35**, 7482–7491
2. Sanders, H., Bode, A. P., Dombrase, F. A., Hoechli, M., and Lentz, B. R. (1985) *Thromb. Res.* **39**, 63–79
3. Sims, P. J., Faioni, E. M., Wiedmer, T., and Shattil, S. J. (1988) *J. Biol. Chem.* **263**, 16265–16272
4. Stenflo, J. (1991) *Blood* **76**, 1637–1651
5. Padmanabhan, K., Padmanabhan, K. P., Tuliński, A., Park, C. H., Bode, W., Huber, R., Blankenhaus, D. T., Cardin, A. D., and Kiesel, W. (1993) *J. Mol. Biol.* **232**, 947–966
